The Sigma Healthcare Ltd (ASX: SIG) share price is in focus after the company announced it has withdrawn from the potential acquisition of The Boots Group. The company says this decision follows a preliminary review of the sale process.
Image source: Getty Images
What did Sigma Healthcare report?
- Sigma has ceased all discussions regarding the purchase of The Boots Group.
- The Board determined the acquisition would not meet current strategic or capital investment objectives.
- International growth remains a key strategic pillar for Sigma.
- Recent Memorandum of Understanding signed with Greenlight Healthcare to explore UK market opportunities.
What else do investors need to know?
Sigma had been considering the Boots acquisition to accelerate its expansion in the UK, leveraging Boots' well-established brand and presence. After initial investigations, Sigma found that the deal did not align with its strategic aims or capital discipline.
The company reiterated its commitment to international growth, particularly in core offshore markets, while continuing to assess new market opportunities. Sigma also stressed its confidence in its current growth strategy, which prioritises strengthening its position in the Australian market.
What's next for Sigma Healthcare?
Looking ahead, Sigma says it will keep assessing acquisition opportunities in Australia and internationally that align with its strategy and offer sustainable returns to shareholders. The company's focus remains on its established plans, including the recent MoU with Greenlight Healthcare, as it seeks growth through disciplined investment and partnering in key markets.
Sigma Healthcare share price snapshot
Over the past 12 months, Sigma Healthcare shares have declined 19%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 4% over the same period.
